Citations

Showing 10 of 108119 citations.

The contribution of behavioral features to caregiver burden in FTLD spectrum disorders
Silverman, Hannah , Ake, Jeannie M., Manoochehri, Masood , Brushaber, Danielle , Devick, Katrina L. , Fields, Julie A. , Forsberg, Leah K. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Heuer, Hilary W. , Kornak, John , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Tartaglia, Maria Carmela , Boxer, Adam L. , Rosen, Howard J. , Cosentino, Stephanie , Huey, Edward D. , Barker, Megan S. , Pascual, Belen , Tartaglia, Maria Carmela , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Lapid, Maria I. , Litvan, Irene , Boeve, Bradley F. , Goldman, Jill

Mayo Clinic

Alzheimer's & Dementia | December 2, 2021 | Volume: 18 | Issue: 9 | Pages: 1635-1649

10.1002/alz.12494 | PMID 34854532 Get It

AbstractIntroductionCaregivers of patients with frontotemporal lobar degeneration (FTLD) spectrum disorders experience tremendous burden, which has been associated with the neuropsychiatric and behavioral features of the disorders.MethodsIn a sample of 558 participants with FTLD spectrum disorders, we performed multiple‐variable regressions to identify the behavioral features that were most strongly associated with caregiver burden, as measured by the Zarit Burden Interview, at each stage of disease.ResultsApathy and disinhibition, as rated by both clinicians and caregivers, as well as clinician‐rated psychosis, showed the strongest associations with caregiver burden, a pattern that was consistent when participants were separated cross‐sectionally by disease stage. In addition, behavioral features appeared to contribute most to caregiver burden in patients with early dementia.DiscussionCaregivers should be provided with early education on the management of the behavioral features of FTLD spectrum disorders. Interventions targeting apathy, disinhibition, and psychosis may be most useful to reduce caregiver burden.
Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease
Buckles, Virginia, Xiong, Chengjie , Bateman, Randall J. , Hassenstab, Jason , Berman, Sarah , Chhatwal, Jasmeer P. , Fagan, Anne M. , Goate, Alison , Graff‐Radford, Neill R. , Marcus, Daniel S., Masters, Colin L. , McCue, Lena , Mori, Hiroshi , Moulder, Krista L., Noble, James M. , Paumier, Katrina L. , Preische, Oliver, Ringman, John M. , Fox, Nick C. , Salloway, Stephen , Vöglein, Jonathan , Morris, John C. , Network, for the Dominantly Inherited Alzheimer's, Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Xiong, Chengjie , Allegri, Ricardo , Danek, Adrian , Ghetti, Bernardino , Jucker, Mathias , McDade, Eric , Schofield, Peter R. , Martins, Ralph N. , Network, for the Dominantly Inherited Alzheimer's, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | December 2, 2021 | Volume: 18 | Issue: 10 | Pages: 1754-1764

10.1002/alz.12505 | PMID 34854530 Get It

AbstractAs prevention trials advance with autosomal dominant Alzheimer disease (ADAD) participants, understanding the similarities and differences between ADAD and “sporadic” late‐onset AD (LOAD) is critical to determine generalizability of findings between these cohorts. Cognitive trajectories of ADAD mutation carriers (MCs) and autopsy‐confirmed LOAD individuals were compared to address this question. Longitudinal rates of change on cognitive measures were compared in ADAD MCs (n = 310) and autopsy‐confirmed LOAD participants (n = 163) before and after symptom onset (estimated/observed). LOAD participants declined more rapidly in the presymptomatic (preclinical) period and performed more poorly at symptom onset than ADAD participants on a cognitive composite. After symptom onset, however, the younger ADAD MCs declined more rapidly. The similar but not identical cognitive trajectories (declining but at different rates) for ADAD and LOAD suggest common AD pathologies but with some differences.
Author response: Histone deacetylase 3 represses cholesterol efflux during CD4+ T-cell activation
Lama, Jyoti , Kizerwetter, Monika , Shapiro, Michael J. , McCue, Shaylene , Kennedy, Madeleine M, Rajcula, Matthew, Wilfahrt, Drew N. , Philips, Rachael L. , Shapiro, Michael Jeremy, Kennedy, Madeleine, Zeng, Hu , Shapiro, Virginia Smith

Mayo Clinic

No container title available | December 2, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.70978.sa2 Get It

Hearing Preservation Microsurgery in Vestibular Schwannomas: Worth Attempting in “Larger” Tumors?
Wallerius, Katherine P. , Macielak, Robert J. , Lawlor, Skye K., Lohse, Christine M. , Neff, Brian A., Gompel, Jamie J. Van , Driscoll, Colin L. W., Link, Michael J. , Carlson, Matthew L. , Van Gompel, Jamie J

Mayo Clinic

The Laryngoscope | December 2, 2021 | Volume: 132 | Issue: 8 | Pages: 1657-1664

10.1002/lary.29968 | PMID 34854492 Get It

Objectives/Hypothesis To review hearing preservation after microsurgical resection of sporadic vestibular schwannomas according to tumor size. Study Design Retrospective cohort. Methods Baseline, intraoperative, and postoperative patient and tumor characteristics were retrospectively collected for a cohort who underwent hearing preservation microsurgery. Serviceable hearing was defined by a pure tone average ≤50 dB and word recognition score ≥50%. Results A total of 243 patients had serviceable hearing preoperatively. Fifty (21%) tumors were confined to the internal auditory canal, and the median tumor size was 16.2 mm (interquartile range [IQR] 11.3–23.2) for tumors with cerebellopontine angle extension. Serviceable hearing was maintained in 64% of patients with tumors confined to the internal auditory canal, 28% with cerebellopontine angle extension <15 mm, and 9% with cerebellopontine angle extension ≥15 mm. On multivariable analysis, the odds ratios of acquiring nonserviceable hearing postoperatively for tumors extending <15 mm and ≥15 mm into the cerebellopontine angle were 5.75 (95% confidence interval [CI] 2.13–15.53; P < .001) and 22.11 (95% CI 7.04–69.42; P < .001), respectively, compared with intracanalicular tumors. Conclusions The strongest predictor of hearing preservation with microsurgery after multivariable adjustment is tumor size. Approximately 10% of patients with tumors ≥15 mm of cerebellopontine angle extension will retain serviceable hearing after microsurgery. Furthermore, hearing preservation techniques offer cochlear nerve preservation and cochlear patency allowing for possible future cochlear implantation. An attempt at hearing preservation, including avoiding surgical approaches that necessarily sacrifice hearing, is worthwhile even in larger tumors if serviceable hearing is present preoperatively. Level of Evidence 4 Laryngoscope , 132:1657–1664, 2022
Unsafe Sharps Disposal Among Insulin-Using Patients With Diabetes Mellitus: An Emerging Global Crisis
Thompson, Bithika , Cook, Curtiss B. , Thompson, Bithika M , Cook, Curtiss B

Mayo Clinic

Journal of Diabetes Science and Technology | December 2, 2021 | Volume: 16 | Issue: 6 | Pages: 1376-1380

10.1177/19322968211059851 | PMID 34852676 Get It

Approximately eight billion therapeutic injections are administered outside of medical treatment facilities annually. The management of diabetes mellitus (DM) includes self-monitoring of blood glucose levels and administration of insulin and injectable non–insulin-related medications. The lancets, needles, and syringes used for DM management are categorized as medical sharps. Improperly discarded medical sharps can cause needlestick injuries in unsuspecting individuals and thereby pose a considerable public health risk. Release of these items into the environment will likely increase with the rising worldwide prevalence of DM, and a public safety crisis will emerge if proper disposal measures are not emphasized. This article reviews the literature from various geopolitical regions and describes how a substantial number of patients with DM improperly discard their sharps. Data support the need to develop multifaceted and innovative approaches to reduce risk associated with improper disposal of DM-related medical sharps into local communities.
Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity
Kane, Jamie , Jansen, Matthijs , Hendrix, Sebastian , Bosmans, Laura A. , Beckers, Linda, Tiel, Claudia M. van , Gijbels, Marion J. , Vries, Carlie J de, Hundelshausen, Philipp von , Vervloet, Marc , Horrevoets, Anton J.G., von Hundelshausen, Philipp , Vervloet, Marc G , Kane, Jamie , Zelcer, Noam , Eringa, Etto C. , van Royen, Niels , Lutgens, Esther

Mayo Clinic

Thrombosis and Haemostasis | December 2, 2021 | Volume: 122 | Issue: 06 | Pages: 1047-1057

10.1055/a-1711-1055 | PMID 34852377 Get It

Abstract Background Galectins have numerous cellular functions in immunity and inflammation. Short-term galectin-2 (Gal-2) blockade in ischemia-induced arteriogenesis shifts macrophages to an anti-inflammatory phenotype and improves perfusion. Gal-2 may also affect other macrophage-related cardiovascular diseases. Objectives This study aims to elucidate the effects of Gal-2 inhibition in atherosclerosis. Methods ApoE −/− mice were given a high-cholesterol diet (HCD) for 12 weeks. After 6 weeks of HCD, intermediate atherosclerotic plaques were present. To study the effects of anti-Gal-2 nanobody treatment on the progression of existing atherosclerosis, treatment with two llama-derived anti-Gal-2 nanobodies (clones 2H8 and 2C10), or vehicle was given for the remaining 6 weeks. Results Gal-2 inhibition reduced the progression of existing atherosclerosis. Atherosclerotic plaque area in the aortic root was decreased, especially so in mice treated with 2C10 nanobodies. This clone showed reduced atherosclerosis severity as reflected by a decrease in fibrous cap atheromas in addition to decreases in plaque size.The number of plaque resident macrophages was unchanged; however, there was a significant increase in the fraction of CD206+ macrophages. 2C10 treatment also increased plaque α-smooth muscle content, and Gal-2 may have a role in modulating the inflammatory status of smooth muscle cells. Remarkably, both treatments reduced serum cholesterol concentrations including reductions in very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein while triglyceride concentrations were unchanged. Conclusion Prolonged and frequent treatment with anti-Gal-2 nanobodies reduced plaque size, slowed plaque progression, and modified the phenotype of plaque macrophages toward an anti-inflammatory profile. These results hold promise for future macrophage modulating therapeutic interventions that promote arteriogenesis and reduce atherosclerosis.
Cardiopulmonary resuscitation training to improve out-of-hospital cardiac arrest survival: addressing potential health inequalities
Khanji, Mohammed Y , Chahal, C. Anwar A. , Akhter, Mohammed Wajid, Patel, Riyaz , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Ricci, Fabrizio

Mayo Clinic

European Journal of Preventive Cardiology | December 1, 2021 | Volume: 29 | Issue: 17 | Pages: 2275-2277

10.1093/eurjpc/zwab214 | PMID 34907418 Get It

Dynamic Aphasia as a Variant of Frontotemporal Dementia
Chandregowda, Adithya, Clark, Heather M., Duffy, Joseph R., Machulda, Mary M., Lowe, Val J., Whitwell, Jennifer L., Josephs, Keith A., Chandregowda, Adithya , Clark, Heather M., Duffy, Joseph R., Machulda, Mary M., Lowe, Val J., Whitwell, Jennifer L., Josephs, Keith A.

Mayo Clinic

Cognitive and Behavioral Neurology | December 1, 2021 | Volume: 34 | Issue: 4 | Pages: 303-318

10.1097/wnn.0000000000000289 | PMID 34851868 Get It

We describe two individuals with progressive verbal difficulty who exhibited impairment of propositional language, with relatively well-preserved auditory comprehension, naming, and repetition—a profile that is consistent with dynamic aphasia. By providing a brief review of pertinent literature and the results from our neurologic, speech and language, neuropsychological, and neuroimaging testing, this report sheds light on the infrequently reported dynamic aphasia in the context of frontotemporal dementia. Our patients’ insights into their verbal difficulty tend to support the notion that dynamic aphasia results from interference at the stage where thoughts are converted into verbal messages—that is, the thought–verbal interface.
Device‐detected nonsustained ventricular tachycardia in adult congenital heart disease without tetralogy of fallot
Doctor, Pezad , Aggarwal, Sanjeev, Lawrence, David , Singh, Gautam K. , Madhavan, Malini , Sriram, Chenni S. , Madhavan, Malini , Sriram, Chenni S , Gupta, Pooja

Mayo Clinic

Pacing and Clinical Electrophysiology | December 1, 2021 | Volume: 45 | Issue: 3 | Pages: 302-313

10.1111/pace.14420 | PMID 34856638 Get It

AbstractObjectivesTo evaluate any association between non‐sustained ventricular tachycardia (NSVT) detected by intra‐cardiac device and clinical outcomes in repaired adult congenital heart disease (ACHD) without tetralogy of Fallot (TOF).BackgroundNSVT portends a higher risk of serious ventricular tachyarrhythmia in TOF. However its clinical significance when incidentally detected by implantable cardiac device is not well elucidated in non‐TOF ACHD cohort.MethodsWe performed a single center, retrospective, longitudinal follow‐up study in repaired ACHD (≥18 years) patients without TOF who hosted a pacemaker or automatic implantable cardiac defibrillator (AICD). The cohort was divided based on presence/absence of device detected NSVT. The primary end‐point was a composite of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), or sudden cardiac death (SCD).ResultsOne hundred fifty eight patients (male 56.3%, median [IQR] age of 35 [28–43] years at last follow‐up] with longitudinal post‐implant follow‐up duration of 8 (5–12) years were included. NSVT was detected in 52 (33%) patients. The primary composite end‐point was more frequent in NSVT group [11.5% vs. 2.8%; p = .04]. Patients with NSVT were (i) older at the time of initial implant (age 25 vs. 18 years, p = .011) and more frequently demonstrated (ii) systemic ventricular dysfunction (44% vs. 26%; p = .015), as well as (iii) history of ventriculotomy (38% vs. 21%; p = .017).ConclusionsIn our repaired ACHD cohort, we noted a significant association between device‐detected‐NSVT and the primary composite end‐point of sustained VT/VF or SCD. Systemic ventricular dysfunction and history of ventriculotomy were more frequent in the NSVT group and likely constituted the clinical milieu.
Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration
Sankar, Ashwini , Swanson, Kristi M. , Zhou, Jiani , Jena, Anupam B. , Shah, Nilay D. , Karaca‐Mandic, Pinar , Ross, Joseph S.

Mayo Clinic

JAMA Network Open | December 1, 2021 | Volume: 4 | Issue: 12 | Pages: e2136662

10.1001/jamanetworkopen.2021.36662 | PMID 34851398 Get It